Announcements
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
- Organovo to Participate in the H.C. Wainwright Global Investment Conference
- Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
More ▼
Key statistics
As of last trade Organovo Holdings Inc (4OR1:DEU) traded at 0.88, 7.06% above its 52-week low of 0.822, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.881 |
---|---|
High | 0.884 |
Low | 0.856 |
Bid | 0.864 |
Offer | 0.909 |
Previous close | 0.997 |
Average volume | 2.87k |
---|---|
Shares outstanding | 10.04m |
Free float | 9.85m |
P/E (TTM) | -- |
Market cap | 9.54m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of May 02 2024.
More ▼